NuVasive (NUVA) : Traders are bullish on NuVasive (NUVA) as it has outperformed the S&P 500 by a wide margin of 2.27% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.46%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 0.43% in the last 1 week, and is up 2.66% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
NuVasive, Inc. is up 17.87% in the last 3-month period. Year-to-Date the stock performance stands at 16.76%. The stock has recorded a 20-day Moving Average of 1.07% and the 50-Day Moving Average is 3.97%.
NuVasive (NASDAQ:NUVA): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $62.91 and $62.80 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $63.50. The buying momentum continued till the end and the stock did not give up its gains. It closed at $63.18, notching a gain of 0.33% for the day. The total traded volume was 268,338 . The stock had closed at $62.97 on the previous day.
Also, Equity Analysts at the UBS maintains the rating on NuVasive (NASDAQ:NUVA). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $60 per share to $71 per share. The rating by the firm was issued on July 28, 2016.
Nuvasive, Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems, including NVM5 and NVJJB, Intra-Operative Monitoring (IOM) services and support; MaXcess, which is an integrated split-blade retractor system, and a variety of implants and biologics.